Why is combination therapy with Glucagon-like peptide-1 (GLP-1) and Dipeptidyl peptidase-4 (DPP-4) inhibitors not recommended?
While it eliminates the need for injections, it does not escape the side effects common to its drug class
Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, Hodson DJ, Jensen RH, Sinclair AJ (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus
The acetyl group protects the molecule from premature breakdown during digestion, allowing it to reach cells more effectively and rapidly increase glutathione levels throughout your body
Metabolic implications of melanocortin agonists
These are two separate skills, and doing one correctly does not guarantee the other